Drug
Tng462
Tng462: highest development phase Phase 1/2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| TNG462 NCT06922591 | Phase 1/2 | PDAC |
Latest
No recent events.
Follow Tng462 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.